We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.60 | 3.06 | 4.00 | - | 77,800 | 08:00:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 8.00 | 10.63M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/4/2024 11:24 | There are very, very few crumbs of comfort to be taken from the results. Line after line it is repeated that each and every sales sector was 'Challenging' As for the US start up, perhaps the timing couldnt have been more wrong? "It was a challenging year in our service business in 2023. As in previous years, the US is by far our most significant market in terms of biopharma companies who outsource their proteomic services to Contract Research Organisations ("CROs") such as Proteome Sciences. Unfortunately, the biopharma market especially in the US was marked by employee layoffs in 2023. According to Fierce Biotech, a company that provides news, analysis and data relating to the biotech sector, biopharma layoffs were 57% up in 2023. This has been confirmed by other Life Science provider companies in their public reporting. The significantly reduced level of financing in biopharma resulted in workforce reductions affecting 187 organisations in 2023. We were in contact and discussing projects with 38 of these that were primarily focused in proteomic pre-clinical and clinical research. Projects were either cancelled before samples were shipped, or significantly delayed pending future financing rounds. This seriously affected our ability to win business." | barry evans | |
10/4/2024 11:12 | We knew the number would be poor as it was flagged earlier, and we also knew that the expences of establishing a presence in America would be high. For myself I am pleased that we are in our biggest market. I am hopeful of the upcomibg stroke test and the real potential of Alzimers especially after the anounced reserch going on in Oxford. In addition the development of new products provides some comfort to me. | wellhonedhutch | |
10/4/2024 10:13 | Someone been on the crack pipe over the other thread. | peverill | |
10/4/2024 10:08 | It is quite sobering to think that there is actually a person IRL that has created the avatars pool2 and wasjobber. | monte1 | |
10/4/2024 10:03 | 59704 see 59703 | barry evans | |
10/4/2024 10:02 | wasjobber, Thermo have been a long term partner of Proteome Sciences for 15 years, but I agree it'll be good to see Thermo taking a more prominent position. After reading the RNS this morning, the future looks brighter than ever. You've already mentioned what I think is probably the most significant RNS statement:- "It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward. STRONG BUY" It's very significant for Proteome Sciences to say that. The value of these biomarkers will be considerable and will project PRM into the £100 millions plus market cap. with ease. I think you are now correct, we are at a pivotal moment for the share price and investors buying now will achieve significant returns, possibly quicker than some may think. | pools2 | |
10/4/2024 09:18 | Grow up! It was a catastrophic performance with the business having gone badly backwards, there is no other way of looking at it. | barry evans | |
10/4/2024 09:15 | It looks like Thermo are getting more involved with PRM. "We continue to innovate in chemistry and will be working on ancillary products to add new functionality for TMTproTM enabled studies through a sponsored research project." | wasjobber | |
10/4/2024 09:01 | Riiiiiiiiiichard? | barry evans | |
10/4/2024 08:49 | Absolutely pitiful. | monte1 | |
10/4/2024 08:49 | Get thee to a nunnery. | monte1 | |
10/4/2024 08:28 | It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward. STRONG BUY | wasjobber | |
10/4/2024 07:45 | My 6p target looks like a stretch for this year! W41 | wrighty41 | |
10/4/2024 07:15 | What are they doing ?? | peverill | |
09/4/2024 08:42 | “ He Has retired.” Was there an announcement? All seems a bit rushed | sandcrab2 | |
09/4/2024 07:11 | Where are the results???,pure shambles of a company and getting worse as time goes by. | peverill | |
08/4/2024 11:19 | The trades look like Bed & ISA's to start the new tax year. Definitely some type of 'put through' and completely market neutral. It's a sign of confidence from investors. | wasjobber | |
08/4/2024 11:16 | Someone has run out of patience!! W41 | wrighty41 | |
07/4/2024 15:12 | He Has retired. | littlejohn277 | |
07/4/2024 13:18 | Anyone know what's happened to the Michael Walters Web site? | sandcrab2 | |
06/4/2024 15:50 | 2M @ 2.6p wouldn't help much with my tax | mashman | |
06/4/2024 01:06 | Tuco, tax. | chutes01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions